Shares of NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) reached a new 52-week low on Monday . The company traded as low as $9.58 and last traded at $9.59, with a volume of 683693 shares changing hands. The stock had previously closed at $9.99.
Analysts Set New Price Targets
NEO has been the subject of several recent research reports. Bank of America decreased their price target on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a report on Wednesday, February 19th. Needham & Company LLC reduced their target price on shares of NeoGenomics from $19.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, February 19th. Jefferies Financial Group initiated coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They set a "buy" rating and a $22.00 price target on the stock. The Goldman Sachs Group reduced their price objective on shares of NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Finally, Benchmark cut shares of NeoGenomics from a "buy" rating to a "hold" rating in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $19.60.
Read Our Latest Analysis on NeoGenomics
NeoGenomics Stock Down 4.2 %
The firm has a market capitalization of $1.30 billion, a PE ratio of -16.29 and a beta of 1.23. The stock has a 50-day simple moving average of $13.92 and a 200-day simple moving average of $15.08. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38.
NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.05). The firm had revenue of $172.00 million during the quarter, compared to analysts' expectations of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. Analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current year.
Institutional Investors Weigh In On NeoGenomics
Several institutional investors have recently made changes to their positions in NEO. Creative Planning raised its stake in shares of NeoGenomics by 42.3% during the 3rd quarter. Creative Planning now owns 23,547 shares of the medical research company's stock valued at $347,000 after purchasing an additional 7,004 shares during the period. Los Angeles Capital Management LLC bought a new position in shares of NeoGenomics in the third quarter valued at approximately $1,101,000. KBC Group NV grew its stake in NeoGenomics by 33.1% during the third quarter. KBC Group NV now owns 4,530 shares of the medical research company's stock valued at $67,000 after acquiring an additional 1,127 shares in the last quarter. Royce & Associates LP increased its holdings in NeoGenomics by 3.2% during the 3rd quarter. Royce & Associates LP now owns 639,476 shares of the medical research company's stock worth $9,432,000 after acquiring an additional 19,780 shares during the period. Finally, Natixis Advisors LLC lifted its stake in NeoGenomics by 54.1% in the 3rd quarter. Natixis Advisors LLC now owns 33,982 shares of the medical research company's stock worth $501,000 after purchasing an additional 11,936 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.
NeoGenomics Company Profile
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Recommended Stories
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
